We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

Fund managers haven’t disclosed any holdings of ASBP yet.

ASBP Hedge Fund Activity: Q1 2026 in Review

12 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q1 2026, worth a combined $372K — down 59% from $900K a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ASBP and 5 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was UBS Group, adding an estimated $228K. The largest seller was Jane Street, exiting entirely with an estimated $90.8K sold.

  • 12 institutional investors held Aspire Biopharma (ASBP) as of Q1 2026, down from 28 in Q4 2025.
  • Funds reported $372K of Aspire Biopharma stock for Q1 2026, down 59% quarter-over-quarter.
  • 5 funds opened new Aspire Biopharma positions in Q1 2026 and 18 closed out, a net change of -13 holders.
  • The largest Aspire Biopharma buyer in Q1 2026 was UBS Group, an estimated $228K added.
  • The largest Aspire Biopharma seller in Q1 2026 was Jane Street, an estimated $90.8K sold.

Based on aggregated 13F filings for Q1 2026.